Fitbit Charge 2

DEVICE4 trials

Sponsors

Dana-Farber Cancer Institute, University Health Network, Toronto, Maxima Medical Center, Maxima Medisch Centrum

Conditions

Coronary Artery DiseaseGynecologic CancerHeart Failure With Reduced Ejection FractionHospitalizationschronic heart failure congestive heart failure

Unknown Phase

The HOPE Trial and the SMART Study

CompletedNCT03022032

Dana-Farber Cancer InstituteGynecologic Cancer

Start: 2017-04-12End: 2020-09-02Updated: 2025-09-09

Validation of a wrist-worn device for the assessment of energy expenditure in patients with chronic heart failure and coronary artery disease

Active, not recruitingNL-OMON45827

Maxima Medisch Centrumchronic heart failure congestive heart failure

Start: 2017-10-11Target: 38Updated: 2024-02-28

Use of Wearables in Hospitalized General Medicine Patients

CompletedNCT03646435

University Health Network, TorontoHospitalizations

Start: 2019-06-12End: 2019-11-01Updated: 2019-12-03

Validation of Two Wrist-worn Devices for the Assessment of Energy Expenditure in Cardiac Patients.

CompletedNCT03951740

Maxima Medical CenterCoronary Artery Disease, Heart Failure With Reduced Ejection Fraction

Start: 2017-10-11End: 2018-06-27Updated: 2019-05-15

Related Papers

Patient-reported and clinician-rated performance status and general health among women with gynecologic cancers on palliative chemotherapy.

Journal of Clinical Oncology2020-05-20